SHELTON, Conn., June 10, 2019 /PRNewswire/ -- NanoViricides, Inc.
(NYSE Amer.: NNVC) (the "Company"), a leader in developing
novel nanomedicines to treat viral diseases, reports that Dr.
Mark Day has been duly appointed as
an Independent Director to its Board of Directors, effective
June 6, 2019. He is also appointed as
a member of the Board's Audit Committee, Nomination Committee, and
Compensation Committee.
Dr. Day has over 16 years of experience in the pharmaceutical
industry with extensive experience in opportunity due diligence and
in-licensing at big pharma as well as out-licensing from biotech.
He continues to serve as Associate Professor, Translational
Neuroscience (Adjunct) at Yale
University.
NanoViricides has recently begun IND-enabling GLP
Safety/Toxicology studies of its lead drug candidate NV-HHV-101, a
broad-spectrum drug candidate in its HerpeCide™ program. The
Company has received favorable response from the US FDA on the
Company's pre-IND application for NV-HHV-101 with the first
indication of shingles rash (VZV). The Company expects that drug
candidates against HSV-1 and HSV-2 should follow soon after the VZV
drug candidate moves into clinical trials. The Company believes
that the expertise of our board directors in pharmaceutical
industry opportunity due diligence and licensing from both big
pharma and small pharma perspectives should prove of great value as
it advances towards human clinical trials and human clinical proof
of the nanoviricides® technology platform for antiviral drug
development.
From April, 2017 to March 2019,
Dr. Day served as the President, Chief Executive Officer and a
Director of Bioasis Technologies, Inc. He led business development,
internal and external R&D, translational medicine and academic
sciences. He was successful in achieving five collaborations with
Big and Mid-pharma at Bioasis. Prior thereto from August 2015 to April
2017, Mark served as the Executive Director, Head of
External Research and Scouting, and from June 2014 to July
2015, as a Senior Director, both at Alexion Pharmaceuticals.
From April 2012 to May 2014, Dr. Day was the Global Lead, Business
Development, Head of Virology and CNS Disorders at Bristol
Meyers-Squibb. From March 2009 to
April 2012 he was Head, Translational
Imaging and Biochemical Biomarkers, at Abbott Laboratories,
Lake Bluff, IL. From 2003 to 2008
he was Discovery Head of CNS Translational Medicine at Wyeth
Research.
Mark holds a Ph.D. in Neuroscience from Cardiff University, UK. Thereafter he was
Senior Research Fellow (PostDoc) in Systems Level Neuroscience in
Episodic Memory and role of NMDA and AMPA receptors in memory
consolidation at the Edinburgh
University, UK.
The Company believes Dr. Day's long history as a pharmaceutical
and biotech executive, particularly in research and development, in
due diligence, and in commercialization, render him well qualified
to serve as a member of the Board of Directors.
"We are very pleased to announce that Dr. Day is joining our
Board. The Company has further improved its depth and breadth of
pharmaceutical industry expertise at the Board level with his
appointment," said Anil R. Diwan, PhD., Executive Chairman of the
Board and President of the Company, adding, "We recently added Mr.
James Sapirstein, a pharma industry
veteran, to the Board. These additions have significantly bolstered
NanoViricides' strength as a pharmaceutical company."
About NanoViricides
NanoViricides, Inc. (www.nanoviricides.com) is a development
stage company that is creating special purpose nanomaterials for
antiviral therapy. The Company's novel nanoviricide® class of drug
candidates are designed to specifically attack enveloped virus
particles and to dismantle them. The Company is developing drugs
against a number of viral diseases including H1N1 swine flu, H5N1
bird flu, seasonal Influenza, HIV, oral and genital Herpes,
shingles and chickenpox, viral diseases of the eye including EKC
and herpes keratitis, Hepatitis C, Rabies, Dengue fever, and Ebola
virus, among others. This press release contains
forward-looking statements that reflect the Company's current
expectation regarding future events. Actual events could differ
materially and substantially from those projected herein and depend
on a number of factors. Certain statements in this release, and
other written or oral statements made by NanoViricides, Inc. are
"forward-looking statements" within the meaning of Section 27A of
the Securities Act of 1933 and Section 21E of the Securities
Exchange Act of 1934. You should not place undue reliance on
forward-looking statements since they involve known and unknown
risks, uncertainties and other factors which are, in some cases,
beyond the Company's control and which could, and likely will,
materially affect actual results, levels of activity, performance
or achievements. The Company assumes no obligation to publicly
update or revise these forward-looking statements for any reason,
or to update the reasons actual results could differ materially
from those anticipated in these forward-looking statements, even if
new information becomes available in the future. Important factors
that could cause actual results to differ materially from the
company's expectations include, but are not limited to, those
factors that are disclosed under the heading "Risk Factors" and
elsewhere in documents filed by the company from time to time with
the United States Securities and Exchange Commission and other
regulatory authorities. Although it is not possible to
predict or identify all such factors, they may include the
following: demonstration and proof of principle in preclinical
trials that a nanoviricide is safe and effective; successful
development of our product candidates; our ability to seek and
obtain regulatory approvals, including with respect to the
indications we are seeking; the successful commercialization of our
product candidates; and market acceptance of our products. (FDA
refers to US Food and Drug Administration. EMA refers to the
European Union's office of European Medicines Agency.)
View original content to download
multimedia:http://www.prnewswire.com/news-releases/nanoviricides-inc-appoints-dr-mark-day-to-its-board-of-directors-300864348.html
SOURCE NanoViricides, Inc.